EASL Clinical Practice Guidelines: management of hepatitis C virus infection European Association For The Study Of The Liver Journal of hepatology 55 (2), 245-264, 2011 | 2460 | 2011 |
Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes P Simmonds, J Bukh, C Combet, G Deléage, N Enomoto, S Feinstone, ... Hepatology 42 (4), 962-973, 2005 | 2246 | 2005 |
EASL Clinical Practice Guidelines: management of chronic hepatitis B European Association For The Study Of The Liver Journal of hepatology 50 (2), 227-242, 2009 | 2064 | 2009 |
EASL recommendations on treatment of hepatitis C 2018 European Association for The Study of The Liver Journal of hepatology 69 (2), 461-511, 2018 | 2038* | 2018 |
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection JG McHutchison, GT Everson, SC Gordon, IM Jacobson, M Sulkowski, ... New England Journal of Medicine 360 (18), 1827-1838, 2009 | 1436 | 2009 |
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection C Hézode, N Forestier, G Dusheiko, P Ferenci, S Pol, T Goeser, ... New England Journal of Medicine 360 (18), 1839-1850, 2009 | 1344 | 2009 |
Statements from the Taormina expert meeting on occult hepatitis B virus infection G Raimondo, JP Allain, MR Brunetto, MA Buendia, DS Chen, M Colombo, ... Journal of hepatology 49 (4), 652-657, 2008 | 1163 | 2008 |
Structural biology of hepatitis C virus F Penin, J Dubuisson, FA Rey, D Moradpour, JM Pawlotsky Hepatology 39 (1), 5-19, 2004 | 997 | 2004 |
EASL recommendations on treatment of hepatitis C: final update of the series☆ JM Pawlotsky, F Negro, A Aghemo, M Berenguer, O Dalgard, G Dusheiko, ... Journal of hepatology 73 (5), 1170-1218, 2020 | 904 | 2020 |
Immunological disorders in C virus chronic active hepatitis: a prospective case‐control study JM Pawlotsky, MB Yahia, C Andre, MC Voisin, L Intrator, ... Hepatology 19 (4), 841-848, 1994 | 700 | 1994 |
Antiviral drug‐resistant HBV: standardization of nomenclature and assays and recommendations for management AS Lok, F Zoulim, S Locarnini, A Bartholomeusz, MG Ghany, ... Hepatology 46 (1), 254-265, 2007 | 685 | 2007 |
Hepatitis C virus infection MP Manns, M Buti, ED Gane, JM Pawlotsky, H Razavi, N Terrault, ... Nature reviews Disease primers 3 (1), 1-19, 2017 | 663 | 2017 |
Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens JM Pawlotsky Gastroenterology 151 (1), 70-86, 2016 | 642 | 2016 |
New hepatitis C therapies: the toolbox, strategies, and challenges JM Pawlotsky Gastroenterology 146 (5), 1176-1192, 2014 | 637 | 2014 |
Use and interpretation of virological tests for hepatitis C JM Pawlotsky Hepatology 36 (5B), s65-s73, 2002 | 610 | 2002 |
Chronic hepatitis B virus infection WK Seto, YR Lo, JM Pawlotsky, MF Yuen The Lancet 392 (10161), 2313-2324, 2018 | 589 | 2018 |
Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study C Charlier, É Perrodeau, A Leclercq, B Cazenave, B Pilmis, B Henry, ... The Lancet Infectious Diseases 17 (5), 510-519, 2017 | 574 | 2017 |
EASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B: 13–14 September, 2002 Geneva, Switzerland Consensus statement (Long version) TE Jury Journal of Hepatology 39, 3-25, 2003 | 570 | 2003 |
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)–NCT01514890 C Hézode, H Fontaine, C Dorival, D Larrey, F Zoulim, V Canva, ... Journal of hepatology 59 (3), 434-441, 2013 | 563 | 2013 |
Characteristics of patients with dual infection by hepatitis B and C viruses JP Zarski, B Bohn, A Bastie, JM Pawlotsky, M Baud, F Bost-Bezeaux, ... Journal of hepatology 28 (1), 27-33, 1998 | 506 | 1998 |